MX2019013926A - Uso novedoso de un agonista del receptor 2 de formil peptido/receptor a4 de lipoxina (fpr2/alx) para el tratamiento de insuficiencia cardiaca. - Google Patents

Uso novedoso de un agonista del receptor 2 de formil peptido/receptor a4 de lipoxina (fpr2/alx) para el tratamiento de insuficiencia cardiaca.

Info

Publication number
MX2019013926A
MX2019013926A MX2019013926A MX2019013926A MX2019013926A MX 2019013926 A MX2019013926 A MX 2019013926A MX 2019013926 A MX2019013926 A MX 2019013926A MX 2019013926 A MX2019013926 A MX 2019013926A MX 2019013926 A MX2019013926 A MX 2019013926A
Authority
MX
Mexico
Prior art keywords
receptor
heart failure
fpr2
lipoxin
alx
Prior art date
Application number
MX2019013926A
Other languages
English (en)
Spanish (es)
Inventor
Ostrowski Jacek
Garcia Ricardo
R Wurtz Nicholas
Leigh Carson Nancy
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62567841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019013926(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2019013926A publication Critical patent/MX2019013926A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2019013926A 2017-05-22 2018-05-22 Uso novedoso de un agonista del receptor 2 de formil peptido/receptor a4 de lipoxina (fpr2/alx) para el tratamiento de insuficiencia cardiaca. MX2019013926A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762509489P 2017-05-22 2017-05-22
PCT/US2018/033783 WO2018217684A1 (en) 2017-05-22 2018-05-22 Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure

Publications (1)

Publication Number Publication Date
MX2019013926A true MX2019013926A (es) 2020-01-20

Family

ID=62567841

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013926A MX2019013926A (es) 2017-05-22 2018-05-22 Uso novedoso de un agonista del receptor 2 de formil peptido/receptor a4 de lipoxina (fpr2/alx) para el tratamiento de insuficiencia cardiaca.

Country Status (15)

Country Link
US (1) US20200069644A1 (cg-RX-API-DMAC7.html)
EP (1) EP3630097A1 (cg-RX-API-DMAC7.html)
JP (1) JP2020520948A (cg-RX-API-DMAC7.html)
KR (1) KR20200006595A (cg-RX-API-DMAC7.html)
CN (1) CN110662538A (cg-RX-API-DMAC7.html)
AU (1) AU2018273382A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019024185A2 (cg-RX-API-DMAC7.html)
CA (1) CA3064291A1 (cg-RX-API-DMAC7.html)
CL (1) CL2019003325A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019013015A2 (cg-RX-API-DMAC7.html)
EA (1) EA201992704A1 (cg-RX-API-DMAC7.html)
IL (1) IL270749A (cg-RX-API-DMAC7.html)
MX (1) MX2019013926A (cg-RX-API-DMAC7.html)
PE (1) PE20200402A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018217684A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102615095B1 (ko) * 2017-06-09 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 피페리디논 포르밀 펩티드 2 수용체 효능제
EP4178946A1 (en) 2020-07-09 2023-05-17 Bristol-Myers Squibb Company Oxopyrrolidine fpr2 agonists
ES2986512T3 (es) 2020-07-09 2024-11-11 Bristol Myers Squibb Co Agonistas del receptor 2 del péptido formil pirazolona
WO2022035923A1 (en) 2020-08-12 2022-02-17 Bristol-Myers Squibb Company Oxopyrrolidine urea fpr2 agonists
WO2022076764A1 (en) * 2020-10-09 2022-04-14 Bristol-Myers Squibb Company Aminoimidazole fpr2 agonists
CN119055775A (zh) * 2022-07-30 2024-12-03 中国医学科学院阜外医院 Jun抑制剂在制备用于治疗射血分数保留的心衰的药物中的用途
CN118831080B (zh) * 2024-09-24 2024-11-22 上海交通大学医学院附属仁济医院 5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005536187A (ja) * 2002-04-03 2005-12-02 バイエル・ヘルスケア・アクチェンゲゼルシャフト N−ホルミルペプチド受容体様1(fprl1)に関連する疾患の診断および治療
EP3305763B1 (en) * 2013-11-28 2019-07-24 Kyorin Pharmaceutical Co., Ltd. Deuterated or isotopically labeled urea derivatives or pharmacologically acceptable salts thereof useful as fprl-1 agonists
KR101645015B1 (ko) * 2014-03-11 2016-08-03 포항공과대학교 산학협력단 Fpr2를 활성화하는 물질을 포함하는, 인슐린 저항성 관련 질환 치료용 조성물

Also Published As

Publication number Publication date
AU2018273382A1 (en) 2020-01-16
IL270749A (en) 2020-01-30
EP3630097A1 (en) 2020-04-08
CL2019003325A1 (es) 2020-04-17
CO2019013015A2 (es) 2020-01-17
BR112019024185A2 (pt) 2020-06-02
WO2018217684A1 (en) 2018-11-29
CN110662538A (zh) 2020-01-07
KR20200006595A (ko) 2020-01-20
CA3064291A1 (en) 2018-11-29
US20200069644A1 (en) 2020-03-05
PE20200402A1 (es) 2020-02-26
JP2020520948A (ja) 2020-07-16
EA201992704A1 (ru) 2020-03-19

Similar Documents

Publication Publication Date Title
CO2019013015A2 (es) Uso novedoso de un agonista del receptor 2 de formil péptido / receptor a4de lipoxina (fpr2 / alx) para el tratamiento de la insuficiencia cardíaca
MX2024004332A (es) Metodos de uso de inhibidores de ehmt2 para tratar o prevenir transtornos sanguíneos.
PH12019550155A1 (en) ARYL HYDROCARBON RECEPTOR (AhR) MODULATOR COMPOUNDS
PH12019550135A1 (en) Aryl hydrocarbon receptor (ahr) modulator compounds
MX2023009483A (es) Anticuerpos monoclonales para usarse para el tratamiento de sinucleinopatia.
PH12019550136A1 (en) ARYL HYDROCARBON RECEPTOR (AhR)MODULATOR COMPOUNDS
MX2017011974A (es) Estabilizacion del 1-cloro-3,3,3-trifluoropropeno.
MY181959A (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
WO2020051375A3 (en) Papd5 inhibitors and methods of use thereof
MX2018006635A (es) Agonistas del receptor 2 de formilpeptido y del receptor 1 de formilpeptido, de piperidinona.
NZ739139A (en) Dopamine d3 receptor antagonists having a bicyclo moiety
MX2018005756A (es) Ubicacion como objetivo del receptor 2 de formilo-peptido/receptor de lipoxina a4 (fpr2/alx) para el tratamiento de enfermedades cardiacas.
PH12017501509A1 (en) Tesofensine, beta blocker combination formulation
MY207387A (en) Methods for the production of methacrylates
PH12021550055A1 (en) Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].
MX2020003243A (es) Métodos para tratar la insuficiencia cardíaca con fracción de eyección preservada.
MX2016014118A (es) Moduladores de receptor de proteina g 40 (gpr40) de pirrolidina para tratamiento de enfermedades tales como diabetes.
PH12019550154B1 (en) Azetidine derivative
TW201612169A (en) (R)-3-((3s,4s)-3-fluoro-4-(4-hydroxyphenyl)piperidin-1-yl)-1-(4-methylbenzyl)pyrrolidin-2-one and its prodrugs for the treatment of psychiatric disorders
ZA202105101B (en) Peptides for treatment and prevention of diabetes and associated disorders
MX2019007217A (es) Peptidos d-enantiomericos para la terapia del dolor cronico y neuropatico.
WO2019040104A3 (en) COMPOUNDS, RELATED SALTS AND METHODS OF TREATING DISEASES
EP3104712A4 (en) Improved process for the synthesis of substituted 1-benzyl-3-(1-(isoxazol-4-ylmethyl)-1h-pyrazol-4-yl)imidazolidine-2,4-diones
MY204088A (en) Method for treating non-compaction cardiomyopathy